Monday, September 22, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Stocks

Genmab Stock: Breakthrough Therapy Sparks 5% Surge

Felix Baarz by Felix Baarz
August 7, 2025
in Stocks
0
Genmab Stock
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Danish biotech firm Genmab saw its shares jump over 5% to $22.70 after announcing groundbreaking Phase 3 trial results for its lymphoma therapy. The EPCORE FL-1 study showed a 79% reduction in disease progression or death risk for patients with relapsed follicular lymphoma when treated with Epcoritamab combined with Rituximab and Lenalidomide. Both primary endpoints were met, with a remarkable 95.7% response rate. The U.S. FDA has granted accelerated review, with approval expected by November 30, potentially making this the first bispecific antibody combo for second-line treatment of the disease in the U.S.

Financial Momentum and Pipeline Strength

Genmab’s revenue grew 19% to $1.64 billion in H1 2025, driven by blockbuster drugs DARZALEX and Kesimpta. Operating profit nearly doubled to $548 million, prompting raised full-year guidance. Beyond Epcoritamab, the company is advancing Rinatabart sesutecan for endometrial cancer, bolstering its oncology portfolio. A strategic partnership with a major pharma firm enhances global commercialization prospects, positioning Genmab as a key player in innovative cancer therapies.

Ad

Genmab Stock: Buy or Sell?! New Genmab Analysis from September 22 delivers the answer:

The latest Genmab figures speak for themselves: Urgent action needed for Genmab investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 22.

Genmab: Buy or sell? Read more here...

Tags: Genmab
Felix Baarz

Felix Baarz

My name is Felix Baarz, and I look back on over fifteen years of experience as a business journalist. I have always been fascinated by the mechanisms and dynamics of global financial markets as well as the complex economic and political interconnections that shape our world. With this passion, I have made a name for myself as an expert on international financial markets and dedicate myself with great commitment to making even the most complex topics understandable and accessible to my readers. My roots lie in Cologne, where I was born and raised. Early on, my curiosity about economic topics and international developments sparked my interest in journalism. After completing my studies, I began my career as a business editor at a respected German trade publication. Here I laid the foundation for my professional career, but my curiosity soon drew me out into the wider world. A turning point in my life was moving to New York, where I lived for six years and gained insight into leading media houses. In this vibrant metropolis, I was able to report firsthand from the heart of the global financial world. From daily developments on Wall Street to major economic policy decisions that make waves worldwide, I had the opportunity to write about central topics that move people and markets alike. This time shaped my perspective and sharpened my view of global interconnections.

Related Posts

Quantum Computing Stock
Stocks

Quantum Computing Stock Dips Despite Major Contract Wins

September 16, 2025
Coinbase Stock
Stocks

Institutional Partnership Fuels Optimism for Coinbase’s Future

September 16, 2025
Strategy Stock
Stocks

MicroStrategy’s Bitcoin Bet Faces Market Skepticism

September 16, 2025
Next Post
Datadog Stock

Datadog Stock: Soars on Strong Earnings and AI Boom

Eli Lilly Stock

Eli Lilly Stock: Surging on Indian Demand and Market Dominance

Yandex Stock

Yandex Stock: Cloud Specialist Nebius Soars on Record Growth

Recommended

TRP stock news

Legacy Private Trust Co. reduces position in Target Co. as dividend payout ratio impresses shareholders

2 years ago
Realty Income Stock

Realty Income’s Dividend Strategy Raises Red Flags for Investors

1 month ago
Finance_Capitalistic

The Role and Importance of Trading Halts in Stock Exchanges

2 years ago
New smart mailbox

Unlocking the Future of Delivery: How Smart Mailbox Platforms are Revolutionizing the Last Mile

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

AAPL Adobe Alibaba Alphabet Amazon AMD AMZN Apple ASML BA BigBear.ai BioNTech Broadcom Coinbase Eli Lilly Fiserv Hims & Hers IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Opendoor Oracle Oxford Lane Capital Palantir PayPal Pepsi Red Cat Robinhood Rocket Lab USA Salesforce Strategy Tesla TSLA Unitedhealth Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Executive Share Sales and Management Shifts Raise Questions at Repay Holdings

EU Data Act Fuels Momentum for Cybersecurity ETF

Dentsply Sirona’s Rocky Road to Recovery

A Closer Look at the VanEck Gaming ETF: A Resilient Tech Niche

Roku Stock: Strong Fundamentals Clash with Institutional Selling

Anavex Alzheimer’s Drug: Breakthrough Data Meets Market Skepticism

Trending

Synchrony Stock
Analysis

Navigating Credit Headwinds: Synchrony’s Strategic Expansion Amid Sector Challenges

by Felix Baarz
September 22, 2025
0

Synchrony Financial is executing a strategic balancing act in the current economic climate. The U.S. financial services...

Vanguard Information Technology Index Fund ETF Shares Stock

Tech Sector Surge: AI and Cloud Computing Fuel Vanguard ETF’s Record Run

September 22, 2025
Gladstone Capital Stock

Gladstone Capital Executes Strategic Debt Refinancing and Rewards Shareholders

September 22, 2025
Repay Holdings Stock

Executive Share Sales and Management Shifts Raise Questions at Repay Holdings

September 22, 2025
iShares Cybersecurity and Tech ETF Stock

EU Data Act Fuels Momentum for Cybersecurity ETF

September 22, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Navigating Credit Headwinds: Synchrony’s Strategic Expansion Amid Sector Challenges
  • Tech Sector Surge: AI and Cloud Computing Fuel Vanguard ETF’s Record Run
  • Gladstone Capital Executes Strategic Debt Refinancing and Rewards Shareholders

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com